Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 38
Filter
1.
Int J Clin Pharm ; 41(5): 1262-1271, 2019 Oct.
Article in English | MEDLINE | ID: mdl-31302885

ABSTRACT

Background Polypharmacy in older patients can lead to potentially inappropriate prescribing. The risk of the latter calls for effective medication review to ensure proper medication usage and safety. Objective Provide insight on the similarities and differences of medication review done in multiple ways that may lead to future possibilities to optimize medication review. Setting This study was conducted in Zuyderland Medical Centre, the second largest teaching hospital in the Netherlands. Method This descriptive study compares the quantity and content of remarks identified by medication review performed by a geriatrician, outpatient pharmacist, and Clinical Decision Support System. The content of remarks is categorized in seven categories of possible pharmacotherapeutic problems: 'indication without medication', 'medication without indication', 'contra-indication/interaction/side-effect', 'dosage problem', 'double medication', 'incorrect medication' and 'therapeutic drug monitoring'. Main outcome measure Number and content of remarks on medication review. Results The Clinical Decision Support System (1.8 ± 0.8 vs. 0.9 ± 0.9, p < 0.001) and outpatient pharmacist (1.8 ± 0.8 vs. 0.9 ± 0.9, p = 0.045) both noted remarks in significantly more categories than the geriatricians. The Clinical Decision Support System provided more remarks on 'double medication', 'dosage problem' and 'contraindication/interaction/side effects' than the geriatrician (p < 0.050), while the geriatrician did on 'medication without indication' (p < 0.001). The Clinical Decision Support System noted significantly more remarks on 'contraindication/interaction/side effects' and 'therapeutic drug monitoring' than the outpatient pharmacist, whereas the outpatient pharmacist reported more on 'indication without medication' and 'medication without indication' than the Clinical Decision Support System (p ≤ 0.007). Conclusion Medication review performed by a geriatrician, outpatient pharmacist, and Clinical Decision Support System provides different insights and should be combined to create a more comprehensive report on medication profiles.


Subject(s)
Aged, 80 and over/statistics & numerical data , Aged/statistics & numerical data , Medication Therapy Management/statistics & numerical data , Decision Support Systems, Clinical , Drug Interactions , Female , Geriatricians , Humans , Inappropriate Prescribing , Male , Netherlands , Pharmacists , Polypharmacy
2.
Ned Tijdschr Geneeskd ; 161: D1354, 2017.
Article in Dutch | MEDLINE | ID: mdl-28270241

ABSTRACT

In order to contain rising healthcare expenditure, the Dutch minister of Health, Welfare, and Sport has agreed with various stakeholders to shift care as much as possible from the expensive specialised care sector to the cheaper primary care sector. Such a shift is only desirable if it constitutes a permanent shift to the primary care sector thereby reducing costs while simultaneously increasing quality of care and the health of the population. In order to prove the success of substitution initiatives, their effects must be compared with the national trend at population level. Longitudinal research is necessary as substitution constitutes a transitional process that requires continuous monitoring and interaction between patients, healthcare providers, insurers, and scientists.


Subject(s)
Delivery of Health Care/methods , Quality of Health Care , Health Expenditures , Humans , Netherlands , Primary Health Care
3.
Psychol Med ; 46(4): 731-44, 2016 Mar.
Article in English | MEDLINE | ID: mdl-26750445

ABSTRACT

BACKGROUND: Minimal efficacy differences have been found between cognitive behavioral therapy (CBT) and psychodynamic therapies for depression, but little is known about patient characteristics that might moderate differential treatment effects. We aimed to generate hypotheses regarding such potential prescriptive factors. METHOD: We conducted post-hoc model-based recursive partitioning analyses alongside a randomized clinical trial comparing the efficacy of CBT and short-term psychodynamic supportive psychotherapy (SPSP). Severely depressed patients received additional antidepressant medication. We included 233 adults seeking treatment for a major depressive episode in psychiatric outpatient clinics, who completed post-treatment assessment. Post-treatment mean Hamilton Depression Rating Scale scores constituted the main outcome measure. RESULTS: While treatment differences (CBT v. SPSP) were minimal in the total sample of patients (d = 0.04), model-based recursive partitioning indicated differential treatment efficacy in certain subgroups of patients. SPSP was found more efficacious among moderately depressed patients receiving psychotherapy only who showed low baseline co-morbid anxiety levels (d = -0.40) and among severely depressed patients receiving psychotherapy and antidepressant medication who reported a duration of the depressive episode of ⩾1 year (d = -0.31), while CBT was found more efficacious for such patients reporting a duration <1 year (d = 0.83). CONCLUSIONS: Our findings are observational and need validation before they can be used to guide treatment selection, but suggest that knowledge of prescriptive factors can help improve the efficacy of psychotherapy for depression. Depressive episode duration and co-morbid anxiety level should be included as stratification variables in future randomized clinical trials comparing CBT and psychodynamic therapy.


Subject(s)
Antidepressive Agents/therapeutic use , Cognitive Behavioral Therapy/methods , Depressive Disorder, Major/therapy , Psychotherapy, Psychodynamic/methods , Adult , Anxiety/psychology , Combined Modality Therapy , Depressive Disorder, Major/psychology , Female , Humans , Male , Middle Aged , Psychotherapy, Brief , Randomized Controlled Trials as Topic , Regression Analysis , Severity of Illness Index , Time Factors , Treatment Outcome
4.
Vaccine ; 33(21): 2477-84, 2015 May 15.
Article in English | MEDLINE | ID: mdl-25843267

ABSTRACT

Most conventional foot-and-mouth disease virus (FMDV) vaccines contain oil-adjuvant. Their potency decreases upon prolonged storage. Intact (146S) FMDV particles can dissociate into 12S degradation products with a concomitant decrease in immunogenicity. We therefore measured virion stability in vaccines using two previously developed ELISAs to separately quantify 12S and 146S particles. Virions completely dissociated into 12S particles within 3 months after oil-emulsification. Dissociation occurred at a much lower rate in a comparable aqueous solution that was not oil-emulsified. Thus, oil-emulsification stimulates virion dissociation, presumably due to the protein denaturing effect of the oil-water interface. In real-time stability studies the stability of oil-adjuvanted virions of four different FMDV strains was significantly increased by addition of sucrose and BSA in a synergistic manner. Contrary to BSA addition, the effect of sucrose addition was concentration dependent. This study illustrates the importance of analysing antigen integrity after oil-emulsification and provides methods for FMDV vaccine stabilization.


Subject(s)
Emulsions , Excipients , Foot-and-Mouth Disease Virus/ultrastructure , Viral Vaccines/chemistry , Virion/ultrastructure , Animals , Drug Stability , Drug Storage , Enzyme-Linked Immunosorbent Assay , Foot-and-Mouth Disease/prevention & control , Serum Albumin, Bovine , Sucrose , Time Factors
5.
Clin Exp Immunol ; 181(2): 306-13, 2015 Aug.
Article in English | MEDLINE | ID: mdl-25079699

ABSTRACT

Atypical haemolytic uraemic syndrome (aHUS) is associated with (genetic) alterations in alternative complement pathway. Nevertheless, comprehensive evidence that the complement system in aHUS patients is more prone to activation is still lacking. Therefore, we performed a thorough analysis of complement activation in acute phase and in remission of this disease. Complement activation patterns of the aHUS patients in acute phase and in remission were compared to those of healthy controls. Background levels of complement activation products C3b/c, C3bBbP and terminal complement complex (TCC) were measured using enzyme-linked immunosorbent assay (ELISA) in ethylenediamine tetraacetic acid (EDTA) plasma. In vitro-triggered complement activation in serum samples was studied using zymosan-coating and pathway-specific assay. Furthermore, efficiencies of the C3b/c, C3bBbP and TCC generation in fluid phase during spontaneous activation were analysed. Patients with acute aHUS showed elevated levels of C3b/c (P < 0·01), C3bBbP (P < 0·0001) and TCC (P < 0·0001) in EDTA plasma, while values of patients in remission were normal, compared to those of healthy controls. Using data from a single aHUS patient with complement factor B mutation we illustrated normalization of complement activation during aHUS recovery. Serum samples from patients in remission showed normal in vitro patterns of complement activation and demonstrated normal kinetics of complement activation in the fluid phase. Our data indicate that while aHUS patients have clearly activated complement in acute phase of the disease, this is not the case in remission of aHUS. This knowledge provides important insight into complement regulation in aHUS and may have an impact on monitoring of these patients, particularly when using complement inhibition therapy.


Subject(s)
Atypical Hemolytic Uremic Syndrome/immunology , Complement Activation , Complement C3b/metabolism , Complement Membrane Attack Complex/metabolism , Acute Disease , Adolescent , Adult , Atypical Hemolytic Uremic Syndrome/blood , Atypical Hemolytic Uremic Syndrome/pathology , Atypical Hemolytic Uremic Syndrome/therapy , Case-Control Studies , Child , Child, Preschool , Complement Activation/drug effects , Complement Factor B/metabolism , Complement Factor H/metabolism , Complement Pathway, Alternative/drug effects , Female , Humans , Infant , Male , Middle Aged , Platelet-Rich Plasma , Protein Isoforms/blood , Remission Induction , Renal Dialysis , Zymosan/pharmacology
6.
Neth J Med ; 71(7): 342-7, 2013 Sep.
Article in English | MEDLINE | ID: mdl-24038559

ABSTRACT

BACKGROUND: Dysregulation of complement activation is the most common cause of the atypical haemolytic uraemic syndrome (aHUS). Many patients with aHUS develop end-stage renal disease and consider kidney transplantation. However, the recurrence rate after transplantation ranges from 45-90% in patients with known abnormalities in circulating complement proteins. It was recently proposed that patients with aHUS should be treated prophylactically with plasma exchange or eculizumab to prevent recurrence after transplantation. METHODS: A case series describing the successful outcome of kidney transplantation without prophylactic therapy in four adult patients with aHUS and a high risk of disease recurrence. Patients received a living donor kidney and immunosuppression consisting of basiliximab induction, low-dose tacrolimus, prednisone and mycophenolate mofetil. Patients received a statin, and were targeted to a low blood pressure preferably using blockers of the renin-angiotensin system. RESULTS: After a follow-up of 16-21 months, none of the patients developed recurrent aHUS. Also, no rejection was observed. CONCLUSIONS: Kidney transplantation in adult patients with aHUS can be successful without prophylactic eculizumab, using a protocol that minimises cold ischaemia time, reduces the risk of rejection and provides endothelial protection. Our data suggest that in patients with aHUS, controlled trials are needed to demonstrate the optimal strategy.


Subject(s)
Hemolytic-Uremic Syndrome/complications , Hemolytic-Uremic Syndrome/prevention & control , Hydroxymethylglutaryl-CoA Reductase Inhibitors/therapeutic use , Immunosuppressive Agents/therapeutic use , Kidney Failure, Chronic/etiology , Kidney Transplantation/methods , Adult , Anti-Inflammatory Agents/therapeutic use , Antibodies, Monoclonal/therapeutic use , Antibodies, Monoclonal, Humanized , Atypical Hemolytic Uremic Syndrome , Basiliximab , Cold Ischemia , Drug Therapy, Combination , Female , Hemolytic-Uremic Syndrome/genetics , Humans , Kidney Failure, Chronic/surgery , Male , Middle Aged , Mycophenolic Acid/analogs & derivatives , Mycophenolic Acid/therapeutic use , Prednisone/therapeutic use , Recombinant Fusion Proteins/therapeutic use , Secondary Prevention , Tacrolimus/therapeutic use , Young Adult
7.
Neth J Med ; 70(3): 121-9, 2012 Apr.
Article in English | MEDLINE | ID: mdl-22516576

ABSTRACT

The haemolytic uraemic syndrome (HUS) is characterised by haemolytic anaemia, thrombocytopenia and acute renal failure. The majority of cases are seen in childhood and are preceded by an infection with Shiga-like toxin producing Escherichia coli (STEC-HUS; so-called typical HUS). Non-STEC or atypical HUS (aHUS) is seen in 5 to 10% of all cases and occurs at all ages. These patients have a poorer outcome and prognosis than patients with STEC-HUS. New insights into the pathogenesis of aHUS were revealed by the identification of mutations in genes encoding proteins of the alternative pathway of the complement system in aHUS patients. Specific information of the causative mutation is important for individualised patient care with respect to choice and efficacy of therapy, the outcome of renal transplantation, and the selection of living donors. This new knowledge about the aetiology of the disease has stimulated the development of more specific treatment modalities. Until now, plasma therapy was used with limited success in aHUS, but recent clinical trials have demonstrated that patients with aHUS can be effectively treated with complement inhibitors, such as the monoclonal anti-C5 inhibitor eculizumab.


Subject(s)
Antibodies, Monoclonal, Humanized/therapeutic use , Complement Inactivating Agents/therapeutic use , Hemolytic-Uremic Syndrome/diagnosis , Hemolytic-Uremic Syndrome/drug therapy , Atypical Hemolytic Uremic Syndrome , Complement System Proteins/genetics , Complement System Proteins/immunology , Hemolytic-Uremic Syndrome/genetics , Humans , Mutation , Prognosis , Treatment Outcome
8.
Vaccine ; 29(15): 2682-90, 2011 Mar 24.
Article in English | MEDLINE | ID: mdl-21316500

ABSTRACT

Intact (146S) foot-and-mouth disease virions (FMDVs) can dissociate into specific (12S) viral capsid degradation products. Using two single-domain antibody fragments that bind specifically to either 146S or 12S particles we developed two ELISAs for the quantification of these particles in FMDV antigen preparations used for vaccine manufacturing. Only O serotype strains are detected in the 146S specific ELISA whereas strains of most serotypes are detected in the 12S specific ELISA. However, the 146S concentration of A and Asia 1 serotype strains could be measured indirectly using the 12S specific ELISA by prior conversion of 146S into 12S particles by heat treatment. This allowed us to demonstrate that addition of the preservative thiomersal to FMDV antigens stimulates the dissociation into 12S particles of O, A and Asia 1 serotype strains upon prolonged storage at 4°C. FMDV dissociation is known to result in a strongly reduced immunogenicity, which was experimentally confirmed here. Therefore, we recommend to omit thiomersal from FMD vaccines to increase its shelf life.


Subject(s)
Foot-and-Mouth Disease Virus/drug effects , Thimerosal/metabolism , Viral Vaccines/chemistry , Virion/drug effects , Animals , Asia , Enzyme-Linked Immunosorbent Assay/methods , Foot-and-Mouth Disease Virus/chemistry , United States , Virion/chemistry , Virology/methods
9.
Vaccine ; 28(19): 3363-70, 2010 Apr 26.
Article in English | MEDLINE | ID: mdl-20206283

ABSTRACT

We have used a novel method, surface-enhanced laser desorption ionization-time of flight-mass spectrometry (SELDI-TOF-MS), to characterize foot-and-mouth disease virus (FMDV) vaccine antigens. Using specific capture with FMDV binding recombinant antibody fragments and tryptic digestion of FMDV antigens the spectral peaks representing the FMDV structural proteins VP1, VP2, VP3 and VP4 were identified. VP1 existed as 2 variants differing by 0.2kDa and VP4 as 8 variants differing by 14-17Da. Such heterogeneities have not been reported earlier. They could represent oxidation of VP4 and N-glycation of VP1. We also detected FMDV proteolysis upon incubation at elevated temperatures and impurities in FMDV antigen preparations. Finally, we could also characterize FMDV antigen present in emulsions with oil adjuvant by SELDI-TOF-MS. Such FMDV antigen retained the VP4 protein which is known to be specifically present in intact (146S) FMDV particles but absent from specific (12S) degradation products. This indicates that virions do not dissociate upon emulsification.


Subject(s)
Antigens, Viral/analysis , Chemistry, Pharmaceutical/methods , Dosage Forms , Foot-and-Mouth Disease Virus/chemistry , Viral Vaccines/chemistry , Animals , Antigens, Viral/immunology , Emulsions , Foot-and-Mouth Disease Virus/immunology , Oils , Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization/methods , Viral Vaccines/immunology
10.
J Chromatogr B Biomed Sci Appl ; 760(1): 129-36, 2001 Aug 25.
Article in English | MEDLINE | ID: mdl-11522055

ABSTRACT

Immobilised metal-ion affinity chromatography (IMAC) is widely used for the purification of recombinant proteins in which a poly-histidine tag is introduced. However, other proteins may also bind to IMAC columns. We describe the use of a washing buffer with a low concentration of EDTA (0.5 mM) for the removal of proteins without histidine tag from IMAC columns. Four histidine-tagged recombinant proteins/protein complexes were purified to homogeneity from cell culture medium of insect cells by using an EDTA washing buffer. The presence of a low concentration of EDTA in washing buffers during IMAC may have a general application in the purification of histidine-tagged proteins.


Subject(s)
Chelating Agents/chemistry , Chromatography, Affinity/methods , Edetic Acid/chemistry , Histidine/chemistry , Recombinant Proteins/isolation & purification , Electrophoresis, Polyacrylamide Gel , Enzyme-Linked Immunosorbent Assay , Metals , Recombinant Proteins/chemistry
11.
Blood ; 98(3): 652-60, 2001 Aug 01.
Article in English | MEDLINE | ID: mdl-11468163

ABSTRACT

The interaction of von Willebrand factor (vWF) with the platelet receptor glycoprotein Ibalpha (GPIbalpha) is important for platelet adhesion at high shear stress. Two functionally important antigenic areas within GPIbalpha were identified through the characterization of 5 new inhibitory anti-GPIb monoclonal antibodies (mAbs). The binding sites of 3 of these anti-GPIb mAbs, which were intercompeting and potently inhibiting shear stress-induced binding of vWF, were mapped within the N-terminal amino acid (aa) 1-59 area by the use of canine-human chimeras. These antibodies, however, had little or no effect (approximately 40% inhibition) on the binding of vWF induced by either botrocetin or ristocetin. On the other hand, the anti-GPIb mAbs 24G10 and 6B4, which blocked GPIb-vWF binding under all conditions examined, bound to 2 different regions of GPIbalpha, aa 1-81 and aa 201-268, respectively. The epitope for 6B4 was further narrowed by phage display revealing 2 sets of peptide sequences aligning within aa 259-262 and aa 230-242. In the latter region of GPIbalpha, the gain-of-function platelet-type von Willebrand disease (PT-vWD) mutations have been identified. Alignment was partially confirmed because the binding of 6B4 to recombinant GPIbalpha fragments carrying either one of the PT-vWD mutations was considerably impaired but not completely abolished. In contrast, mAb 24G10 bound more strongly to mutant PT-vWD GPIbalpha. However, although 24G10 competed with 6B4 for binding to platelets, it bound to an epitope within aa 1-81 of GPIbalpha. In conclusion, 2 functionally important areas within GPIbalpha were identified: one localized within the leucine-rich repeat N-terminal aa 1-59 area and one composed of residues aa 1-81 in close contact with aa 201-268. Moreover, further support is provided for the existence of an intramolecular interaction between the N-terminal flanking (aa 1-81) and C-terminal flanking (aa 201-268) regions. (Blood. 2001;98:652-660)


Subject(s)
Antibodies, Blocking/immunology , Antibodies, Monoclonal/immunology , Antibodies, Monoclonal/metabolism , Epitope Mapping/methods , Platelet Glycoprotein GPIb-IX Complex/immunology , Repetitive Sequences, Amino Acid , Animals , Binding Sites , Binding, Competitive , Crotalid Venoms/pharmacology , Dogs , Humans , Peptide Library , Platelet Adhesiveness/drug effects , Platelet Adhesiveness/immunology , Platelet Glycoprotein GPIb-IX Complex/chemistry , Platelet Glycoprotein GPIb-IX Complex/metabolism , Protein Binding , Protein Structure, Tertiary , Recombinant Fusion Proteins/chemistry , Recombinant Fusion Proteins/immunology , Recombinant Fusion Proteins/metabolism , Ristocetin/pharmacology , Stress, Mechanical , von Willebrand Factor/metabolism
12.
Acta Virol ; 44(2): 99-108, 2000 Apr.
Article in English | MEDLINE | ID: mdl-10989701

ABSTRACT

Sequences of UL44 genes of strains HSZP, KOS and 17 of herpes simplex virus 1 (HSV-1) were determined and the amino acid sequences of corresponding glycoproteins (gC) were deduced. In comparison with the 17 strain, the HSZP strain showed specific changes in 3 nucleotides and in 2 amino acids (aa 139 and 147, both from Arg to Trp) in the antigenic locus LII. The change at aa 147 was situated within the GAG-binding epitope. In a similar comparison, KOS strain had changes in 3 nucleotides and 3 amino acids (aa 3, 14, and 300). The UL44 genes of HSZP and KOS strains were expressed in insect Sf-21 cells by means of the baculovirus (Bac-to-Bac) expression system. As shown by immunoblot analysis, both the recombinant baculoviruses (B1-HSZP and B6-KOS) expressed a glycosylated gC, the M(r) of which (116 K) was lower than that of gC synthesized in Vero cells (129 K) infected with strains HSZP or KOS. In addition, smaller gC-specific proteins (of apparent M(r) of 50-58 K and 98 K) corresponding to a non-glycosylated precursor polypeptide and/or incomplete forms of the partially glycosylated gC were found. When Balb/c mice were immunized with Sf-21 cells expressing gC, the recombinant gC-HSZP represented a more efficient immunogen possibly due to its stronger expression in these cells. The corresponding gC-HSZP antiserum reacted in enzyme-linked immunosorbent assay (ELISA) equally well with HSZP and KOS virion antigens and neutralized HSZP strain at a low titer. Both gC-HSZP and gC-KOS antisera detected the homologous as well as the heterologous gC antigens in Vero cells regardless whether infected with strains HSZP, KOS or 17, revealing the presence of gC from 6 to 16 hrs post infection (p.i.) in the cytoplasm, on the nuclear membrane and at the cell surface.


Subject(s)
Herpesvirus 1, Human/chemistry , Viral Envelope Proteins/chemistry , Animals , Antibodies, Monoclonal/immunology , Antibodies, Viral/immunology , Baculoviridae , Base Sequence , Cell Line , Chlorocebus aethiops , DNA, Viral , Enzyme-Linked Immunosorbent Assay/methods , Gene Expression , Genetic Vectors , Herpesvirus 1, Human/immunology , Herpesvirus 1, Human/isolation & purification , Humans , Molecular Sequence Data , Spodoptera , Vero Cells , Viral Envelope Proteins/genetics , Viral Envelope Proteins/immunology
13.
Virology ; 261(1): 96-105, 1999 Aug 15.
Article in English | MEDLINE | ID: mdl-10441558

ABSTRACT

The complex formation between glycoproteins H (gH) and L (gL) of herpes simplex virus type 1 (HSV-1) was studied by using five recombinant baculoviruses expressing open reading frames that contain deletions in the coding region of the extracellular domain of gH. In addition, the gH-deletion mutants contained a C-terminal tag. Complex formation of gL and the gH-deletion mutants was studied by immunoprecipitations with anti-tag monoclonal antibody (MAb) A16 and with the gH-specific MAbs 37S, 46S, and 52S. All gH-deletion mutants were complexed to gL when analyzed by MAb A16. MAb 37S precipitated complexes between gL and the two gH-deletion mutants that contain the epitope of this MAb. When the gH conformation-dependent MAbs 46S and 52S were used, gL was coprecipitated together with the gH-deletion mutant lacking amino acids 31-299, but gL was not coprecipitated with the gH-deletion mutant lacking amino acids 31-473. The data from the precipitation studies do allow at least two interpretations. There is either one site for gL binding on gH (residue 300-473) or gL contacts multiple regions of gH. We were unable to demonstrate gL-dependent cell surface expression of either of the gH-deletion mutants. This suggests that the coassociation of gH with gL is necessary but not sufficient for transport of gH to the cell surface.


Subject(s)
Herpesvirus 1, Human/metabolism , Viral Envelope Proteins/metabolism , Animals , Antibodies, Monoclonal , Baculoviridae/genetics , Cell Line , Flow Cytometry , Gene Deletion , Herpesvirus 1, Human/chemistry , Herpesvirus 1, Human/genetics , Herpesvirus 1, Human/physiology , Humans , Immunoblotting , Mutation , Precipitin Tests , Spodoptera/virology , Viral Envelope Proteins/chemistry , Viral Envelope Proteins/genetics
14.
Virology ; 251(2): 317-26, 1998 Nov 25.
Article in English | MEDLINE | ID: mdl-9837796

ABSTRACT

The induction of type I interferons by most RNA viruses is initiated by virus-derived double-stranded (ds)RNA. However, retro- and DNA-viruses, which do not synthesize dsRNA, must rely on different mechanisms of induction. For human immunodeficiency virus type 1 (HIV-1), recombinant glycoproteins 120 or 160 suffice to induce interferon (IFN)-alpha in blood-derived lymphocytes [H. Ankel, M. R. Capobianchi, C. Castilletti, and F. Dianzani (1994). Virology 205, 34-43]. Here we show that for herpes simplex virus type 1 (HSV-1) recombinant glycoprotein, gD is the major inducer, whereas gB, gC, gE, gG, gI, and the complex of gH and gL are poor inducers. The recombinant extramembrane fragment of gD was sufficient to induce IFN-alpha levels comparable to that of intact virus. Like with HIV-1, induction was inhibited by a monoclonal antibody that recognizes cerebrosides and sulfatides. Furthermore, monoclonal antibodies specific for the chemokine receptors CCR3 and CXCR4 also blocked induction. We conclude that HSV-1 induces IFN-alpha by interaction of its glycoprotein gD with appropriate receptors on IFN-producing cells. Based on the known receptor roles of galactosyl cerebrosides and chemokine receptors in HIV infection, such structures on IFN-producing cells could also participate in the induction of IFN-alpha by HSV-1.


Subject(s)
Hemagglutinins, Viral/metabolism , Herpesvirus 1, Human/metabolism , Interferon-alpha/biosynthesis , Receptors, CXCR4/metabolism , Receptors, Chemokine/metabolism , Viral Envelope Proteins/metabolism , Animals , Antibodies, Monoclonal/metabolism , Antibodies, Viral/metabolism , Cell Line , Cell Membrane/metabolism , Hemagglutinins, Viral/immunology , Humans , Receptors, CCR3 , Receptors, CXCR4/immunology , Receptors, Chemokine/immunology , Recombinant Proteins/metabolism , Spodoptera , Viral Envelope Proteins/immunology
15.
J Virol ; 71(3): 2285-91, 1997 Mar.
Article in English | MEDLINE | ID: mdl-9032364

ABSTRACT

In mammalian cells, formation of heterooligomers consisting of the glycoproteins H and L (gH and gL) of herpes simplex virus type 1 is essential for the cell-to-cell spread of virions and for the penetration of virions into cells. We examined whether formation of gH1/gL1 heterooligomers and cell surface expression of the complex occurs in insect cells. Three recombinant baculoviruses, expressing gL1, gH1, and truncated gH1 (gH1t), which lacks the transmembrane region, were constructed. It was shown that recombinant gH1/gL1 and gH1t/gL1 heterooligomers were produced in insect cells. As in mammalian cells, gH1 and gH1t were not detected on the surfaces of insect cells in the absence of gL1. When coexpressed with gL1, recombinant gH1 was displayed on the surfaces of insect cells. Coexpression of gH1t and gL1 resulted in secretion of the gH1t/gL1 complex into the cell culture medium, indicating that gH1t is also transported to the surfaces of insect cells. Our results indicate that the process of folding and intracellular transport of gH1 and gL1 is comparable in insect cells and mammalian cells and that the baculovirus expression system can be used to examine the complex formation and the intracellular transport of gH1 and gL1. The availability of secreted gH1t/gL1 complex offers the opportunity to further investigate the immunological properties of this complex.


Subject(s)
Herpesvirus 1, Human/metabolism , Viral Envelope Proteins/metabolism , Animals , Baculoviridae/genetics , Biological Transport , Cell Line , Cell Membrane/metabolism , Chlorocebus aethiops , Genetic Vectors , Herpesvirus 1, Human/genetics , Humans , Recombinant Fusion Proteins/genetics , Recombinant Fusion Proteins/metabolism , Recombination, Genetic , Spodoptera/cytology , Vero Cells , Viral Envelope Proteins/genetics
16.
J Virol ; 67(9): 5435-42, 1993 Sep.
Article in English | MEDLINE | ID: mdl-8350404

ABSTRACT

The processing and protective capacity of E1, an envelope glycoprotein of hog cholera virus (HCV), were investigated after expression of different versions of the protein in insect cells by using a baculovirus vector. Recombinant virus BacE1[+] expressed E1, including its C-terminal transmembrane region (TMR), and generated a protein which was similar in size (51 to 54 kDa) to the size of E1 expressed in swine kidney cells infected with HCV. The protein was not secreted from the insect cells, and like wild-type E1, it remained sensitive to endo-beta-N-acetyl-D-glucosaminidase H (endo H). This indicates that E1 with a TMR accumulates in the endoplasmic reticulum or cis-Golgi region of the cell. In contrast, recombinant virus BacE1[-], which expressed E1 without a C-terminal TMR, generated a protein that was secreted from the cells. The fraction of this protein that was found to be cell associated had a slightly lower molecular mass (49 to 52 kDa) than wild-type E1 and remained endo H sensitive. The high-mannose units of the secreted protein were trimmed during transport through the exocytotic pathway to endo H-resistant glycans, resulting in a protein with a lower molecular mass (46 to 48 kDa). Secreted E1 accumulated in the medium to about 30 micrograms/10(6) cells. This amount was about 3-fold higher than that of cell-associated E1 in BacE1[-] and 10-fold higher than that of cell-associated E1 in BacE1[+]-infected Sf21 cells. Intramuscular vaccination of pigs with immunoaffinity-purified E1 in a double water-oil emulsion elicited high titers of neutralizing antibodies between 2 and 4 weeks after vaccination at the lowest dose tested (20 micrograms). The vaccinated pigs were completely protected against intranasal challenge with 100 50% lethal doses of HCV strain Brescia, indicating that E1 expressed in insect cells is an excellent candidate for development of a new, safe, and effective HCV subunit vaccine.


Subject(s)
Classical Swine Fever Virus/metabolism , Classical Swine Fever/prevention & control , Vaccines, Synthetic/immunology , Viral Envelope Proteins/immunology , Viral Vaccines/immunology , Animals , Base Sequence , Cell Line , Classical Swine Fever/immunology , Classical Swine Fever Virus/genetics , Classical Swine Fever Virus/immunology , Cloning, Molecular , Endoplasmic Reticulum/metabolism , Gene Expression , Golgi Apparatus/metabolism , Kidney , Molecular Sequence Data , Moths , Oligodeoxyribonucleotides , Recombinant Proteins/biosynthesis , Recombinant Proteins/immunology , Swine , Transfection , Vaccines, Synthetic/biosynthesis , Viral Vaccines/biosynthesis
18.
Diagn Imaging Clin Med ; 54(6): 285-97, 1985.
Article in English | MEDLINE | ID: mdl-3851704

ABSTRACT

472 computed tomographic (CT) examinations in 448 patients were reviewed for depression of the wall of the trachea and mainstem bronchi. Depression was defined as a neutral term, not indicating pressure exerted upon the wall. Such depressions appeared to occur very frequently as a variant. Special attention is paid to the so-called azygos vein indentation. The most marked depression variants in our series are reproduced. When a depression is found in contiguity with a pathological mass and does not exceed the range of the variants, one cannot be sure that the mass is indeed the cause of this depression. In patients with bronchogenic carcinoma, depression of the wall of the trachea or mainstem bronchus seems to be no better sign for the metastatic nature of lymphadenopathy than size per se.


Subject(s)
Bronchography , Tomography, X-Ray Computed , Trachea/diagnostic imaging , Azygos Vein/diagnostic imaging , Bronchi/anatomy & histology , Carcinoma, Bronchogenic/diagnostic imaging , Carcinoma, Bronchogenic/pathology , Humans , Lung Neoplasms/diagnostic imaging , Lung Neoplasms/pathology , Lymphatic Metastasis , Mediastinum , Trachea/anatomy & histology
19.
Diagn Imaging Clin Med ; 54(5): 229-39, 1985.
Article in English | MEDLINE | ID: mdl-3850009

ABSTRACT

472 computed tomographic (CT) examinations in 448 patients were reviewed for mucoid pseudotumors. In 10 patients (2%), an intraluminal density was indirectly proven to be mucous material by negative bronchoscopy and/or repeat CT. Mucoid pseudotumors can easily be differentiated from CT artifacts and from intraluminal neoplasms with extraluminal extension. Differentiation from true intraluminal neoplasmata may be difficult. No definite diagnostic criteria can be proposed since there were no true intraluminal neoplasms present in this series. Nonetheless, several characteristic radiological features of mucoid pseudotumors are discussed. When a potential mucoid pseudotumor is found in a CT examination either the CT scans in question should be repeated after vigorous coughing or an intraluminal neoplasm should be excluded by bronchoscopy. Starting from the CT examination, in the case of bronchogenic carcinoma of the central airways, the intraluminal extent of the tumor might be overestimated due to mucous material proximal to the tumor.


Subject(s)
Bronchial Neoplasms/diagnostic imaging , Mucus , Tomography, X-Ray Computed , Trachea/diagnostic imaging , Adolescent , Adult , Aged , Bronchi/anatomy & histology , Child , Female , Humans , Male , Middle Aged , Tracheal Neoplasms/diagnostic imaging
20.
Am J Obstet Gynecol ; 146(4): 371-3, 1983 Jun 15.
Article in English | MEDLINE | ID: mdl-6407322

ABSTRACT

Thirty New Zealand White female rabbits underwent tubal resection and reanastomosis for comparison of conventional microsurgery and laser microsurgical techniques. The rabbits were divided into three groups. The first group of 10 rabbits had 3 cm of tissue resected by knife from each uterine horn; the cut ends were then reanastomosed in one layer with 8-0 Vicryl sutures with the use of the operating microscope. The second group of 10 rabbits had 3 cm of tissue resected by laser from each uterine horn; the cut ends were then reanastomosed in one layer with 8-0 Vicryl. The third group of 10 rabbits had 3 cm of tissue resected by laser from each uterine horn; the cut ends were then reanastomosed by "welding" the tissues with the laser. All rabbits in the first group became pregnant. Only four in the second group became pregnant, but none in the third group became pregnant. It is concluded that the carbon dioxide laser beam as used in this study has no place in tubal resection and reconstruction.


Subject(s)
Fallopian Tubes/surgery , Laser Therapy , Microsurgery , Animals , Carbon Dioxide , Female , Lasers/adverse effects , Male , Pregnancy , Rabbits , Salpingitis/etiology
SELECTION OF CITATIONS
SEARCH DETAIL
...